Analyst Consensus ?
ConsensusBuy33 ratings
Bullish1854.5%
Neutral1545.5%
Bearish00.0%
Cardinal Health, Inc. · CAH · FY2025 Q1 · Calendar Q4 2024
Cardinal Health raises FY2025 outlook as Pharma leads growth
The supplied analysis supports a constructive but conditional view: Cardinal Health's Pharma and specialty growth, operational initiatives, and raised guidance strengthen the earnings trajectory, while GMPD costs and supply-chain risks remain important tests.
Reported Before market openNYSEHealthcare
$58.75B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.88
Consensus $1.62
EPS surprise
+16.0%
Reported versus consensus
Reported revenue
$52.28B
Consensus $50.90B
Revenue surprise
+2.7%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+7.0%
Event window
SPY move
+0.4%
Same window
Abnormal move
+6.6%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
+5.5%
Up to 20 sessions
CAHSPY benchmark
Ask FN2 about CAH FY2025 Q1
Transcript, numbers and history already loaded
Why did CAH rise 7.0% after beating EPS estimates in FY2025 Q1?What changed in CAH's guidance and outlook in FY2025 Q1?Give me the bull and bear case for CAH after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management reported stronger Pharma performance, raised fiscal 2025 EPS and adjusted free cash flow guidance, and highlighted a pending $1.1 billion Integrated Oncology Network acquisition. GMPD profitability was pressured by unexpected health-and-welfare costs, although the improvement plan remained on track.
Guidance delta
Management raised fiscal 2025 EPS guidance to $7.75-$7.90 and adjusted free cash flow guidance to $1-$1.5 billion, from the prior quarter's $7.55-$7.70 EPS outlook.
Key takeaways
- Pharma profit growth and strength across brand, specialty, GLP-1, and generics supported the quarter.
- GMPD faced health-and-welfare cost pressure, while management said its improvement plan remains on track.
- The company is investing in specialty, at-Home solutions, logistics technology, domestic syringe capacity, and oncology services.
Management priorities
- Advance the GMPD Improvement Plan and expand domestic syringe production.
- Launch and expand at-Home, specialty, and advanced-therapy offerings, including the Kangaroo OMNI pump and Advanced Therapy Connect.
- Complete and integrate the pending Integrated Oncology Network acquisition and continue disciplined capital allocation.
Follow CAH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$253.71Current
$53Low
$192.16Average
$292High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 16, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Aug 13, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 13, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 12, 2026 |
| UBS | Buy | Buy | Maintain | Aug 12, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 12, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Aug 12, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 12, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 12, 2026 |
| Baird | Outperform | Outperform | Maintain | Aug 12, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 2, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Aug 12, 2025 |
| Jefferies | Buy | Hold | Upgrade | Feb 5, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Nov 4, 2024 |
| Argus Research | Buy | Buy | Maintain | Sep 11, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Jun 12, 2023 |
| Cowen & Co. | Market Perform | Market Perform | Maintain | Aug 16, 2022 |
| CFRA | Hold | Hold | Maintain | May 11, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Dec 16, 2019 |
| Argus | Hold | Buy | Downgrade | Aug 27, 2019 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Nov 16, 2018 |
| RBC Capital | Perform | Sector Perform | Maintain | Sep 19, 2017 |
| Tigress Financial | Neutral | Neutral | Maintain | Apr 28, 2017 |
| William Blair | Market Perform | Outperform | Downgrade | Apr 19, 2017 |
| Needham | Hold | Hold | Maintain | Apr 4, 2017 |
| Goldman Sachs | Neutral | Buy | Downgrade | Sep 16, 2016 |
| Avondale Partners | Outperform | Market Outperform | Maintain | Apr 18, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Jan 6, 2016 |
| FBR Capital | Outperform | Outperform | Maintain | Mar 10, 2015 |
| Bank of America | Buy | Buy | Maintain | Dec 29, 2014 |
| Sterne Agee | Buy | Neutral | Upgrade | Nov 6, 2013 |
| ISI Group | Buy | Strong Buy | Downgrade | Mar 20, 2013 |
| Lazard | Neutral | Buy | Downgrade | Mar 19, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $253.71. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Ryan Halsted | $276 | $234.98 | +8.8% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $275 | $234.16 | +8.4% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $265 | $236.64 | +4.4% | Aug 12, 2026 |
| Evercore ISI | Analyst unavailable | $270 | $240.26 | +6.4% | Aug 12, 2026 |
| UBS | Analyst unavailable | $280 | $240.26 | +10.4% | Aug 12, 2026 |
| Wells Fargo | Stephen Baxter | $277 | $240.26 | +9.2% | Aug 12, 2026 |
| Mizuho Securities | Steven Valiquette | $250 | $240.26 | -1.5% | Aug 12, 2026 |
| Robert W. Baird | Eric Coldwell | $274 | $240.26 | +8.0% | Aug 12, 2026 |
| Leerink Partners | Analyst unavailable | $292 | $240.26 | +15.1% | Aug 11, 2026 |
| UBS | Analyst unavailable | $274 | $226.42 | +8.0% | Jul 20, 2026 |
| Robert W. Baird | Analyst unavailable | $248 | $195.08 | -2.3% | May 1, 2026 |
| Evercore ISI | Elizabeth Anderson | $240 | $215.13 | -5.4% | Apr 8, 2026 |
| Leerink Partners | Michael Cherny | $275 | $222.28 | +8.4% | Mar 9, 2026 |
| Barclays | Analyst unavailable | $258 | $224.82 | +1.7% | Feb 24, 2026 |
| Wells Fargo | Analyst unavailable | $256 | $225.76 | +0.9% | Feb 10, 2026 |
| Morgan Stanley | Analyst unavailable | $255 | $229.63 | +0.5% | Feb 6, 2026 |
| Robert W. Baird | Analyst unavailable | $252 | $228.78 | -0.7% | Feb 6, 2026 |
| UBS | Kevin Caliendo | $260 | $228.63 | +2.5% | Feb 6, 2026 |
| Mizuho Securities | Steven Valiquette | $235 | $227.18 | -7.4% | Feb 6, 2026 |
| Evercore ISI | Elizabeth Anderson | $260 | $227.18 | +2.5% | Feb 5, 2026 |
| Morgan Stanley | Erin Wright | $245 | $210.39 | -3.4% | Jan 29, 2026 |
| Robert W. Baird | Eric Coldwell | $250 | $211.98 | -1.5% | Jan 14, 2026 |
| Leerink Partners | Michael Cherny | $240 | $208.24 | -5.4% | Jan 13, 2026 |
| Mizuho Securities | Steven Valiquette | $222 | $201.11 | -12.5% | Jan 12, 2026 |
| Barclays | Glen Santangelo | $243 | $198.88 | -4.2% | Dec 8, 2025 |
| Mizuho Securities | Steven Valiquette | $210 | $190.22 | -17.2% | Nov 3, 2025 |
| Jefferies | Analyst unavailable | $220 | $190.22 | -13.3% | Nov 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $220 | $191.29 | -13.3% | Oct 31, 2025 |
| UBS | Analyst unavailable | $220 | $192.07 | -13.3% | Oct 31, 2025 |
| Robert W. Baird | Analyst unavailable | $232 | $192.36 | -8.6% | Oct 31, 2025 |
| Argus Research | Analyst unavailable | $189 | $148.1 | -25.5% | Aug 22, 2025 |
| Leerink Partners | Michael Cherny | $186 | $146.3 | -26.7% | Aug 12, 2025 |
| Jefferies | Brian Tanquilut | $150 | $157.66 | -40.9% | Aug 12, 2025 |
| Morgan Stanley | Erin Wright | $181 | $161.41 | -28.7% | Jun 13, 2025 |
| Wells Fargo | Stephen Baxter | $179 | $155.48 | -29.4% | Jun 3, 2025 |
| Argus Research | Kristina Ruggeri | $148 | $125.17 | -41.7% | Feb 4, 2025 |
| Robert W. Baird | Eric Coldwell | $140 | $112.3 | -44.8% | Sep 23, 2024 |
| Argus Research | David Toung | $125 | $112.36 | -50.7% | Sep 11, 2024 |
| Deutsche Bank | George Hill | $119 | $107.91 | -53.1% | Aug 16, 2024 |
| Evercore ISI | Elizabeth Anderson | $115 | $107.71 | -54.7% | Aug 15, 2024 |
| Morgan Stanley | Erin Wright | $119 | $106.36 | -53.1% | Aug 15, 2024 |
| Mizuho Securities | Ann Hynes | $110 | $107.39 | -56.6% | Aug 15, 2024 |
| Robert W. Baird | Eric Coldwell | $137 | $107.33 | -46.0% | Aug 15, 2024 |
| Wells Fargo | Stephen Baxter | $101 | $106.36 | -60.2% | Aug 15, 2024 |
| CFRA | Garrett Nelson | $111 | $99.01 | -56.2% | Jun 11, 2024 |
| Robert W. Baird | Eric Coldwell | $129 | $94.75 | -49.2% | May 29, 2024 |
| Argus Research | David Toung | $115 | $97.43 | -54.7% | May 15, 2024 |
| Robert W. Baird | Eric Coldwell | $128 | $102.98 | -49.5% | May 3, 2024 |
| Robert W. Baird | Eric Coldwell | $134 | $110.12 | -47.2% | Apr 5, 2024 |
| Morgan Stanley | Erin Wright | $90 | $92.99 | -64.5% | Aug 15, 2023 |
| Wolfe Research | Tim Anderson | $127 | $79.18 | -49.9% | Apr 12, 2023 |
| Robert W. Baird | Baird Baird | $94 | $78.61 | -62.9% | Feb 8, 2023 |
| Credit Suisse | Analyst unavailable | $92 | $80.14 | -63.7% | Feb 3, 2023 |
| Morgan Stanley | Analyst unavailable | $86 | $78.12 | -66.1% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $79 | $79.22 | -68.9% | Nov 22, 2022 |
| UBS | Analyst unavailable | $78 | $68.51 | -69.3% | Aug 29, 2022 |
| Evercore ISI | Elizabeth Anderson | $68 | $55.83 | -73.2% | May 20, 2022 |
| Deutsche Bank | George Hill | $51 | $58.27 | -79.9% | May 8, 2022 |
| Morgan Stanley | Ricky Goldwasser | $74 | $62.96 | -70.8% | Apr 16, 2022 |
| Barclays | Steve Valiquette | $63 | $53.09 | -75.2% | Jan 17, 2022 |
| UBS | Kevin Caliendo | $61 | $48.84 | -76.0% | Nov 17, 2021 |
| Cowen & Co. | Charles Rhyee | $53 | $50.28 | -79.1% | Aug 11, 2021 |
| Bank of America Securities | Michael Cherny | $56 | $49.2 | -77.9% | Aug 5, 2021 |
Track every rating change on CAH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items.…
Historical context
All CAH earningsLatest beats and misses
Who reports nextBeat on EPS
Get the CAH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-16T04:20:42.086651+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-16T04:20:42.083926+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-16. For educational purposes only; not investment advice.